Rostenberg I, Guízar-Vázquez J, Peñaloza R
J Natl Cancer Inst. 1978 Oct;61(4):961-5.
The glycosylation of IgG and alpha1-antitrypsin (alpha1-AT) was studied by their precipitation with concanavalin A in a codified serum panel from the National Cancer Institute (Bethesda, Md.) and the Mayo Clinic (Rochester, Minn.). The serum panel was composed of samples from 98 patients with cancer of the lung, prostate gland, or gastrointestinal tract, 50 samples from patients with benign inflammatory diseases from the same organs as those of the cancer patients, and 41 samples from apparently healthy smokers. The assay for alpha1-AT revealed statistically significant differences in levels between the patients with cancer, the patients with benign diseases, and the smokers. However, tests revealed no statistically significant difference in IgG levels among the three groups. These results suggest that cancer may alter the glycosylation of alpha1-AT. The possibility remains that the test for alpha1-AT can detect genetic differences among individuals, but studies of families are needed before a final conclusion can be made.
通过使用刀豆球蛋白A沉淀法，对来自美国国立癌症研究所（马里兰州贝塞斯达）和梅奥诊所（明尼苏达州罗切斯特）的一组标准化血清样本中的免疫球蛋白G（IgG）和α1-抗胰蛋白酶（α1-AT）的糖基化进行了研究。该血清样本组包括98例肺癌、前列腺癌或胃肠道癌患者的样本、50例与癌症患者相同器官患有良性炎症性疾病患者的样本，以及41例明显健康吸烟者的样本。α1-抗胰蛋白酶检测显示，癌症患者、良性疾病患者和吸烟者之间的水平存在统计学显著差异。然而，检测显示三组之间IgG水平无统计学显著差异。这些结果表明，癌症可能会改变α1-抗胰蛋白酶的糖基化。α1-抗胰蛋白酶检测仍有可能检测个体之间的基因差异，但在得出最终结论之前，还需要对家族进行研究。
